$2500 | Single User
$5000 | Site License
$7500 | Enterprise License

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016

Published by Global Data: 29 Jun 2016 | 27032 | In Stock

Introduction

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016

  • Table of Contents

    Table of Contents 2

    List of Tables 4

    List of Figures 5

    Report Guidance 6

    Clinical Trials by Region 7

    Clinical Trials and Average Enrollment by Country 8

    Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

    Top Five Countries Contributing to Clinical Trials in Europe 11

    Top Countries Contributing to Clinical Trials in North America 12

    Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

    Top Five Countries Contributing to Clinical Trials in Central and South America 14

    Clinical Trials by G7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 15

    Clinical Trials by Phase in G7 Countries 16

    Clinical Trials in G7 Countries by Trial Status 17

    Clinical Trials by E7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 18

    Clinical Trials by Phase in E7 Countries 19

    Clinical Trials in E7 Countries by Trial Status 20

    Clinical Trials by Phase 21

    In Progress Trials by Phase 22

    Clinical Trials by Trial Status 23

    Clinical Trials by End Point Status 24

    Subjects Recruited Over a Period of Time 25

    Clinical Trials by Sponsor Type 26

    Prominent Sponsors 27

    Top Companies Participating in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials 28

    Prominent Drugs 29

    Latest Clinical Trials News on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) 30

    Jun 20, 2016: Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) 30

    Jun 12, 2016: Pfizer Announces Final Results From Inotuzumab Ozogamicin Pivotal Phase 3 Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia 30

    Jun 10, 2016: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia 31

    Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association 32

    Jun 10, 2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting 32

    Jun 04, 2016: Juno Therapeutics’ Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL 33

    Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society 33

    Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers 34

    Jun 02, 2016: Seattle Children T-Cell Immunotherapy Clinical Trial for Children With Relapsed Leukemia Shows 93% Complete Remission Rate 35

    May 31, 2016: Kite Pharma to Highlight Key Data from Engineered CAR T Cell Therapy Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting 35

    May 19, 2016: Syros Pharmaceuticals to Present on SY-1365 at 21st Congress of the European Hematology Association 36

    May 18, 2016: Juno Therapeutics to Highlights New Efficacy, Safety, and Durability data for JCAR-014 at the 2016 American Society of Clinical Oncology Annual Meeting 37

    May 18, 2016: Juno Therapeutics to Highlight First clinical results for JCAR017 at the 2016 American Society of Clinical Oncology Annual Meeting 37

    May 18, 2016: Juno Therapeutics to Highlight JCAR-015 at the 2016 American Society of Clinical Oncology Annual Meeting 37

    Apr 20, 2016: Juno Therapeutics Presents Clinical Data of JCAR018 at American Association for Cancer Research (AACR) Annual Meeting 2016 38

    Apr 18, 2016: Immunomedics Announces Potent Anti-Tumor Activities with IMMU-114 in Preclinical Study in Acute and Chronic Leukemia 38

    Apr 14, 2016: Juno Therapeutics Announces Updated clinical data for CD22 CAR T cell product candidate, JCAR018 at the American Association for Cancer Research Annual Meeting 39

    Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101 40

    Clinical Trial Profile Snapshots 42

    Appendix 1271

    Abbreviations 1271

    Definitions 1271

    Research Methodology 1272

    Secondary Research 1272

    About GlobalData 1273

    Contact Us 1273

    Disclaimer 1273

    Source 1274

List Of Tables
in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016

List of Tables

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2016* 7

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14

Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2016* 21

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List Of Figures, Charts and Diagrams
in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016

List of Figures

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2016* 7

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14

Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

GlobalData Methodology 1272

Additional Details

Publisher

Global Data

Publisher Information

Reference

27032 | GDHC3491CTIDB

Number of Pages

1274

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2016SummaryGlobal...
20 Apr 2016 by Global Data USD $2,500 More Info
Acute Pain Global Clinical Trials Review, H1, 2016
Acute Pain Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Acute ...
20 Apr 2016 by Global Data USD $2,500 More Info
Acute Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2016
Acute Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2016SummaryGlobalData's clini...
29 Feb 2016 by Global Data USD $2,500 More Info
Acute Stress Disorder Global Clinical Trials Review, H2, 2015
Acute Stress Disorder Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial repo...
16 Dec 2015 by Global Data USD $2,500 More Info
Acute Injury Global Clinical Trials Review, H2, 2015
Acute Injury Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report, “Acut...
09 Dec 2015 by Global Data USD $2,500 More Info
Acute Respiratory Failure Global Clinical Trials Review, H2, 2015
Acute Respiratory Failure Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial ...
25 Nov 2015 by Global Data USD $2,500 More Info
Acute and Sub-Acute Bursitis Global Clinical Trials Review, H2, 2015
Acute and Sub-Acute Bursitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical tri...
25 Nov 2015 by Global Data USD $2,500 More Info
Altitude Sickness (Acute mountain sickness) Global Clinical Trials Review, H2, 2015
Altitude Sickness (Acute mountain sickness) Global Clinical Trials Review, H2, 2015SummaryGlobalData...
25 Nov 2015 by Global Data USD $2,500 More Info
Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015
Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's ...
30 Oct 2015 by Global Data USD $2,500 More Info

This report is published by Global Data

Download Free Report Summary PDF

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data